Lack of Interaction between Lansoprazole and Propranolol, a Pharmacokinetic and Safety Assessment

Journal of Clinical Pharmacology

Volumn 40, Issue 3, 2000, Pages 301-308

  Karol, Michael D ^a   Locke, Charles S ^a   Cavanaugh, John H ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; LANSOPRAZOLE; OMEPRAZOLE; PROPRANOLOL; PROTON PUMP;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG INTERACTION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; MALE; OMEPRAZOLE; PROPRANOLOL; PROTON PUMPS;

EID: 0034146712     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008856     Document Type: Article

References (28)

1. NIH Consensus Development Panel: Helicobacter pylori in peptic ulcer disease. Journal of the American Medical Association 1994;272: 65-69.
2. Iwahi T, Satoh H, Nakao M, et al: Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobactor pylori. Antimicrobial Agents and Chemotherapy 1991;35:490-496.
3. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Archives of Internal Medicine 1993;153:154-183.
4. Alderman MH: Which antihypertensive drugs first - and why! Journal of the American Medical Association 1992;267:2786-2787.
5. Walle T, Walle K, Mathur R, et al: Propranolol metabolism in normal subjects: association with steroid hormones. Clinical Pharmacology and Therapeutics 1994;56:127-132.
6. Walle T, Walle U, Cowart T, et al: Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clinical Pharmacology and Therapeutics 1989;46:257-263.
7. Gibaldi M, PerrierD: Pharmacokinetics. Vol. 15, 2nd ed. New York: Marcel Dekker, 1982.
8. SAS Institute, Inc.: SAS/STAT User's Guide: Statistics. Version 6, vol. 2. Cary, NC: SAS Institute, Inc., 1990.
9. Pichard L, Curi-Pedrosa R, Bonfils C, et al: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Molecular Pharmacology 1995;47(2):410-418.
10. Pearce RE, Rodrigues AD, Goldstein JA, et al: Identification of the human P450 enzymes involved in lansoprazole metabolism. Journal of Pharmacology and Experimental Therapeutics 1996;277(2):805-816.
11. Kornhauser DM, Wood AJJ, Vestal RE, et al: Biological determinants of propranolol disposition in man. Clinical Pharmacology and Therapeutics 1978;23:165-174.
12. Walle T, Walle UK, Olanoff LS: Quantitative account of propranolol metabolism in urine of normal man. Drug Metabolism and Disposition 1985;13(2):204-209.
13. Ward SA, Walle T, Walle UK, et al: Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydorxylase activities. Clinical Pharmacology and Therapeutics 1989;45:72-79.
14. Masubuchi Y, Hosokawa S, Horie T, et al: Cytochrome P450 isozymes in propranolol metabolism in human liver microsomes: the role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metabolism and Disposition 1994;22(6):909-915.
15. Barrett AM, Cullum VA: The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. British Journal of Pharmacology 1968;34:43-55.
16. Walle T, Walle UK, Wilson MJ, et al: Stereoselective ring oxidation of propranolol in man. British Journal of Clinical Pharmacology 1984;18:741-747.
17. Henry D, Brent P, Whyte I, et al: Propranolol steady-state pharmacokinetics are unaltered my omeprazole. European Journal of Clinical Pharmacology 1987;33:369-373.
18. Andersson T, Lundborg P, Regårdh CG: Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. European Journal of Clinical Pharmacology 1991;40:61-65.
19. Lennard MS, Silas HJ, Freestone S, et al: Oxidation phenotype: a major determinant of metoprolol metabolism and response. New England Journal of Medicine 1982;307:1558-1560.
20. Granneman GR, Karol MD, Locke CS, et al: Pharmacokinetic interaction between lansoprazole and theophylline. Therapeutic Drug Monitoring 1995;17(5):460-464.
21. Granneman GR, Winters EP, Locke CS, et al: Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics. Gastroenterology 1991;100(5):A75.
22. Fuchs W, Sennewald R, Klotz U: Lansoprazole does not affect the bioavailability of oral contraceptives. British Journal of Clinical Pharmacology 1994;38:376-380.
23. Karol MD, Mayersohn M, Eason CJ, et al: Evaluation of interaction potential between lansoprazole and clarithromycin (Biaxin®) in normal subjects. Paper presented at the American College of Gastroenterology, 60th Annual Scientific Meeting, New York, 1995.
24. Braeckman RA, Winters EP, Cohe A, et al: Lack of effect of lansoprazole on warfarin pharmacokinetics and anticoagulation effect in healthy subjects. Pharmaceutical Research 1991;8(Suppl.):S-295.
25. Karol MD, Locke C, Cavanaugh JH: Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin. J Clin Pharmacol 1999;39:1283-1289.
26. Lefebvre R, Flouvat B, Karolac-Tamisier S, et al: Influence of lansoprazole treatment on diazepam plasma concentrations. Clinical Pharmacology and Therapeutics 1992;52:458-463.
27. St. Peter JV, Awni WM, Granneman GR, et al: The effects of lansoprazole on the disposition of antipyrine and indocyanine green in normal human subjects. American Journal of Therapeutics 1995;2: 561-568.
28. Cavanaugh JH, Park YK, Awni WM, et al: Effect of lansoprazole on antipyrine and ICG pharmacokinetics. Gastroenterology 1991; 100(5):A40.